Top ten stories in the pharmaceutical industry this week
pharmafile | September 23, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | top ten
It’s Friday (and print day for the Pharmafocus October edition!) and its been a pretty explosive week, from new and exciting technologies to some very heated controversies, check out the top ten most read articles on Pharmafile.com over the past seven days:
10. Sanofi reveals promising data for relapsing remitting MS treatment
Data from an extension study of Lemtrada showed continued benefits even after five years since last treatment.
9. Sanofi accuses MSD of US patent infringement
French firm takes legal action to protect its Lantus and Lantus SoloStar products.
8. Allergan expands NASH portfolio with $1.7 billion in acquisitions
The company acquired biotech Tobira Therapeutics and privately-held Akarna Therapeutics for a total of over £1.7 billion in 24 hours.
7. Precision medicine reveals ‘Achilles heel’ in chronic myeloid leukaemia
Scientists at the University of Glasgow make their second significant breakthrough in the treatment of the disease by utilising precision medicine.
6. “First of its kind” manufacturing campus to bring 500 jobs to Ireland
New ‘BioPark’ will generate 500 jobs and provide prefabricated, off-the-shelf bio-manufacturing facilities.
5. NICE rejects expanded treatment indication for Roche’s Esbriet
The decision leaves patients with no treatment option to slow the progression of idiopathic pulmonary fibrosis until lung function has been lost.
4. AstraZeneca and Microsoft to develop ‘drag and drop’ cancer simulation
Cloud-based computerised modelling system promises to enable scientists to streamline their work and conduct experiments at much higher volume and speed.
3. EpiPen CEO appears before US lawmakers to defend “sickening” price hikes
Mylan CEO Heather Bresch says EpiPen is not profitable, despite the company recording $11 billion in sales.
2. GSK appoints Emma Walmsley as CEO
Walmsley replaces Sir Andrew Witty to become most powerful woman in the FTSE100.
1. Feature: UK Biopharma and life after Brexit
Paul Ranson, of global law firm Morgan Lewis’ London Life Sciences Practice examines how UK biopharma must now adapt to a changing landscape.
Related Content
Top Ten most popular articles on Pharmafile.com this week
As the year winds to a close, excitement is rising around the efficacy and availability …
Top Ten most popular articles on Pharmafile.com this week
The top ten news stories this week focus on herd immunity, as the Director of …
Pharmafile.com’s weekly COVID-19 news round-up
The coronavirus news this week focuses on the development of treatments to alleviate symptoms of …
